RE:RE:RE:bought back for cancellation ... 633,150 sharesMrMugsy wrote: gudisgood wrote: MrMugsy wrote: | d 2022-02-08 17:31 Tx date 2022-01-31 | $GUD
Knight Therapeutics Inc. | Knight Therapeutics Inc. 1 - Issuer Direct Ownership | Common Shares 38 - Redemption, retraction, cancellation, repurchase |
-633,150 vol | 0 |
I believe we should be close to 117M shares outstanding. Maybe essentially there already if buybacks continued similarly in February.
IF we get $10M in cash inflow from operations for Q4 (I have no idea if this is going to happen as there are too many unknown factors, and it's relatively meaningless in the long run), it's $50M for the whole year, and that's around $0.42 per share (current shares outstanding), for a company with a porftolio of growing products, growing market, and in general is essentially "just getting started".
Cash inflow was a
negative $17M in 2020 if my numbers are correct.
Add to that $1.28 per share in cash and marketable securities. I like where we are right now. :)
FWIW ...
Cashflow for 2020 as shown in the annual report on page 23 (YTD numbers)
1. negative $12.2M in cash from operations
2. positive $101.353M in cash from investing
3. negative $29.2333M in cash used in financing
Total cashflow of positive $59.915M
I thought I had my OP cash flow number (-17M) wrong in my Excel file.
However, if you look at OP cash flow from each individual 2020 quarterly report, the numbers are (roughly):
Q1: -21M
Q2: 8M
Q3: -8M
Q4: 4M
That should be around 17M but the year-end report shows 12M.
Seems like the Q2 report shows -13M YTD meanwhile the Q3 shows -8.4M for the quarter and -16.5M for YTD. Something changes there. What am I not getting?